세계의 과다색소침착 치료 시장 규모, 점유율 및 동향 분석 보고서 : 치료 유형별, 최종 사용자별, 질병 유형별, 지역별 전망 및 예측(2023-2030년)

Global Hyperpigmentation Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By End User, By Disorder Type . By Regional Outlook and Forecast, 2023 - 2030

US $ 3,600 ￦ 5,108,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,320 ￦ 6,130,000

PDF (Multi User License)

PDF 보고서를 동일 기업의 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,048 ￦ 8,582,000

PDF (Corporate User License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 과다색소침착 치료 시장 규모는 예측 기간 동안 8.2%의 연평균 복합 성장률(CAGR)로 성장하여 2030년까지 93억 달러에 이를 것으로 예상됩니다.

또한, 가처분 소득이 높은 사람들은 피부과 의사나 피부 관리 전문가가 제공하는 전문적인 과다색소침착 치료를 받을 수 있습니다. 여기에는 레이저 치료, 화학적 필링 및 기타 고급 개입과 같은 절차가 포함됩니다. 따라서 가처분 소득 수준이 높기 때문에 시장이 크게 확대될 것으로 예상됩니다.

그러나 치료비 부담의 문제는 다양한 인구 통계 및 사회경제적 그룹 간의 치료 접근성 격차로 이어질 수 있습니다. 이로 인해 과다색소침착 치료의 혜택이 불평등하게 분배될 수 있습니다. 치료 접근성 격차는 특정 인구 집단이 충분한 서비스를 받지 못하거나 경제적 제약으로 인해 치료를 받지 못할 수 있기 때문에 종합적인 시장 성장을 달성하는 데 어려움을 초래할 수 있습니다. 따라서 높은 치료 비용으로 인해 시장 성장이 둔화될 수 있습니다.

또한, 봉쇄, 제한 및 생산 시설의 일시적 폐쇄로 인해 원자재 및 완제품 공급이 중단되었습니다. 이러한 혼란으로 인해 과다색소침착 치료 제품의 생산 및 유통이 지연되어 시장에서 특정 제제, 국소 약물 및 장치의 가용성에 영향을 미쳤습니다. 따라서 코로나19 팬데믹은 시장에 중간 정도의 영향을 미쳤습니다.

목차

제1장 시장 범위와 조사 방법

• 시장의 정의
• 목적
• 시장 범위
• 세분화
• 조사 방법

제2장 시장 요람

• 주요 하이라이트

제3장 시장 개요

• 서론
  • 개요
    • 시장 구성과 시나리오
• 시장에 영향을 미치는 주요 요인
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장이 해결해야 할 과제
• Porter의 Five Forces 분석

제4장 세계 시장 : 치료 유형별

• 세계의 국소 약제 시장 : 지역별
• 세계의 광선 요법 시장 : 지역별
• 세계의 미세박피술 시장 : 지역별

제5장 세계 시장 : 최종사용자별

• 세계의 피부과 클리닉 시장 : 지역별
• 세계의 병원 시장 : 지역별
• 세계의 기타 시장 : 지역별

제6장 세계 시장 : 질환 유형별

• 세계의 기미 시장 : 지역별
• 세계의 검버섯 시장 : 지역별
• 세계의 기타 시장 : 지역별

제7장 세계 시장 : 지역별

• 북미
  • 북미 시장 : 국가별
    • 미국
    • 캐나다
    • 멕시코
    • 기타 북미
• 유럽
  • 유럽 시장 : 국가별
    • 독일
    • 영국
    • 프랑스
    • 러시아
    • 스페인
    • 이탈리아
    • 기타 유럽
• 아시아태평양
  • 아시아태평양 시장 : 국가별
    • 중국
    • 일본
    • 인도
    • 한국
    • 싱가포르
    • 말레이시아
    • 기타 아시아태평양
• 라틴아메리카/중동 및 아프리카
  • 라틴아메리카/중동 및 아프리카 시장 : 국가별
    • 브라질
    • 아르헨티나
    • 아랍에미리트(UAE)
    • 사우디아라비아
    • 남아프리카공화국
    • 나이지리아
    • 기타 라틴아메리카/중동 및 아프리카

제8장 기업 개요

• Vivier Pharma Inc
• Pierre Fabre SA
• Aerolase
• L'Oreal SA
• The Procter & Gamble Company
• Galderma SA
• CP Skin Health Group, Inc(The Colgate Palmolive Company)
• Trophy Skin Products LLC
• The Alchemee LLC(Taro Pharmaceutical Industries Ltd)
• Episciences, Inc

제9장 과다색소침착 치료 시장을 위한 성공 필수 조건

LSH

영문 목차

영문목차

The Global Hyperpigmentation Treatment Market size is expected to reach $9.3 billion by 2030, rising at a market growth of 8.2% CAGR during the forecast period.

There is a notable increase in awareness about skincare practices among the population in Mexico. The Mexican population has a growing cosmetic consciousness, with individuals expressing a desire for clear and even-toned skin. Consequently, the North America region would generate a revenue of USD 1,818.2 Million in 2022. The high prevalence of hyperpigmentation in North America creates a substantial demand for effective treatment solutions. North America boasts advanced healthcare infrastructure, including well-equipped dermatological clinics and hospitals.

Social media platforms amplify skincare trends and routines, including Instagram, TikTok, and YouTube. Influencers and skincare enthusiasts showcase their hyperpigmentation treatment journeys, fostering awareness and inspiring others to explore similar interventions. Therefore, the hyperpigmentation treatment market is expanding significantly due to the social media influence and beauty standards.

Additionally, Individuals with a higher disposable income can afford professional hyperpigmentation treatments dermatologists and skincare professionals offer. This includes procedures such as laser therapy, chemical peels, and other advanced interventions. Thus, because of the higher level of disposable income, the market is anticipated to increase significantly.

However, Affordability challenges may contribute to disparities in treatment access across different demographics and socioeconomic groups. This can lead to unequal distribution of hyperpigmentation treatment benefits. Disparities in treatment access create challenges for achieving inclusive market growth, as certain population segments may be underserved or excluded due to financial constraints. Thus, high treatment costs can slow down the growth of the market.

Furthermore, Lockdowns, restrictions, and temporary closures of production facilities led to interruptions in the supply of raw materials and finished products. This disruption resulted in delays in the production and distribution of hyperpigmentation treatment products, affecting the availability of certain formulations, topical agents, and devices in the market. Thus, the COVID-19 pandemic had a moderate effect on the market.

By Treatment Type Analysis

By treatment type, the market is categorized into topical agent, photo therapy, and microdermabrasion. In 2022, the topical agent segment held a 44.40 % revenue share in the market. Topical agents offer a non-invasive treatment option, eliminating the need for surgical procedures or more aggressive interventions. The non-invasive nature of topical treatments appeals to individuals who prefer less downtime and minimal discomfort. This characteristic contributes to the widespread adoption of the topical agent segment in the hyperpigmentation treatment market.

By End User Analysis

On the basis of end user, the market is divided into hospitals, dermatological clinics, and others. The hospitals segment garnered a 40.6 % revenue share in the market in 2022. Hospitals often house advanced dermatological departments equipped with state-of-the-art technologies and skilled healthcare professionals. These facilities offer comprehensive services for diagnosing and treating various skin conditions, including hyperpigmentation.

By Disorder Type Analysis

Based on disorder type, the market is classified into age spot, melasma, and other. In 2022, the melasma segment witnessed a 47.81 % revenue share in the market. Melasma is a common pigmentary disorder, and its prevalence has steadily increased. Factors like hormonal changes, genetic predisposition, and sun exposure contribute to the rising incidence of melasma. Melasma is often hormonally mediated and is commonly associated with pregnancy, oral contraceptive use, and hormonal therapies. The condition predominantly affects women, particularly those in their reproductive years.

By Regional Analysis

Region-wise, the treatment market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region acquired a 28.57 % revenue share in the treatment market. There is a growing awareness of skincare practices and a shift towards proactive skin health management in the Asia Pacific. Adopting Western beauty standards has influenced skincare preferences in the Asia Pacific region. The increasing emphasis on aesthetics and appearance enhancement drives the demand for cosmetic procedures in the Asia Pacific.

List of Key Companies Profiled

• Vivier Pharma Inc.
• Pierre Fabre S.A
• Aerolase
• L'Oreal S.A.
• CP Skin Health Group, Inc. (The Colgate Palmolive Company)
• Trophy Skin Products LLC
• The Alchemee LLC (Taro Pharmaceutical Industries Ltd.)
• Episciences, Inc.
• The Procter and Gamble Company
• Galderma S.A.

Global Hyperpigmentation Treatment Market Report Segmentation

By Treatment Type

• Topical Agent
• Photo Therapy
• Microdermabrasion

By End User

• Dermatological Clinics
• Hospitals
• Others

By Disorder Type

• Melasma
• Age Spot
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1.Market Scope & Methodology

• 1.1Market Definition
• 1.2Objectives
• 1.3Market Scope
• 1.4Segmentation
  • 1.4.1Global Hyperpigmentation Treatment Market, by Treatment Type
  • 1.4.2Global Hyperpigmentation Treatment Market, by End User
  • 1.4.3Global Hyperpigmentation Treatment Market, by Disorder Type
  • 1.4.4Global Hyperpigmentation Treatment Market, by Geography
• 1.5Methodology for the research

Chapter 2.Market at a Glance

• 2.1Key Highlights

Chapter 3.Market Overview

• 3.1Introduction
  • 3.1.1Overview
    • 3.1.1.1Market Composition and Scenario
• 3.2Key Factors Impacting the Market
  • 3.2.1Market Drivers
  • 3.2.2Market Restraints
  • 3.2.3Market Opportunities
  • 3.2.4Market Challenges
• 3.3Porter's Five Forces Analysis

Chapter 4.Global Hyperpigmentation Treatment Market by Treatment Type

• 4.1Global Topical Agent Market by Region
• 4.2Global Photo Therapy Market by Region
• 4.3Global Microdermabrasion Market by Region

Chapter 5.Global Hyperpigmentation Treatment Market by End User

• 5.1Global Dermatological Clinics Market by Region
• 5.2Global Hospitals Market by Region
• 5.3Global Others Market by Region

Chapter 6.Global Hyperpigmentation Treatment Market by Disorder Type

• 6.1Global Melasma Market by Region
• 6.2Global Age Spot Market by Region
• 6.3Global Others Market by Region

Chapter 7.Global Hyperpigmentation Treatment Market by Region

• 7.1North America Hyperpigmentation Treatment Market
  • 7.1.1North America Hyperpigmentation Treatment Market by Treatment Type
    • 7.1.1.1North America Topical Agent Market by Country
    • 7.1.1.2North America Photo Therapy Market by Country
    • 7.1.1.3North America Microdermabrasion Market by Country
  • 7.1.2North America Hyperpigmentation Treatment Market by End User
    • 7.1.2.1North America Dermatological Clinics Market by Country
    • 7.1.2.2North America Hospitals Market by Country
    • 7.1.2.3North America Others Market by Country
  • 7.1.3North America Hyperpigmentation Treatment Market by Disorder Type
    • 7.1.3.1North America Melasma Market by Country
    • 7.1.3.2North America Age Spot Market by Country
    • 7.1.3.3North America Others Market by Country
  • 7.1.4North America Hyperpigmentation Treatment Market by Country
    • 7.1.4.1US Hyperpigmentation Treatment Market
      • 7.1.4.1.1US Hyperpigmentation Treatment Market by Treatment Type
      • 7.1.4.1.2US Hyperpigmentation Treatment Market by End User
      • 7.1.4.1.3US Hyperpigmentation Treatment Market by Disorder Type
    • 7.1.4.2Canada Hyperpigmentation Treatment Market
      • 7.1.4.2.1Canada Hyperpigmentation Treatment Market by Treatment Type
      • 7.1.4.2.2Canada Hyperpigmentation Treatment Market by End User
      • 7.1.4.2.3Canada Hyperpigmentation Treatment Market by Disorder Type
    • 7.1.4.3Mexico Hyperpigmentation Treatment Market
      • 7.1.4.3.1Mexico Hyperpigmentation Treatment Market by Treatment Type
      • 7.1.4.3.2Mexico Hyperpigmentation Treatment Market by End User
      • 7.1.4.3.3Mexico Hyperpigmentation Treatment Market by Disorder Type
    • 7.1.4.4Rest of North America Hyperpigmentation Treatment Market
      • 7.1.4.4.1Rest of North America Hyperpigmentation Treatment Market by Treatment Type
      • 7.1.4.4.2Rest of North America Hyperpigmentation Treatment Market by End User
      • 7.1.4.4.3Rest of North America Hyperpigmentation Treatment Market by Disorder Type
• 7.2Europe Hyperpigmentation Treatment Market
  • 7.2.1Europe Hyperpigmentation Treatment Market by Treatment Type
    • 7.2.1.1Europe Topical Agent Market by Country
    • 7.2.1.2Europe Photo Therapy Market by Country
    • 7.2.1.3Europe Microdermabrasion Market by Country
  • 7.2.2Europe Hyperpigmentation Treatment Market by End User
    • 7.2.2.1Europe Dermatological Clinics Market by Country
    • 7.2.2.2Europe Hospitals Market by Country
    • 7.2.2.3Europe Others Market by Country
  • 7.2.3Europe Hyperpigmentation Treatment Market by Disorder Type
    • 7.2.3.1Europe Melasma Market by Country
    • 7.2.3.2Europe Age Spot Market by Country
    • 7.2.3.3Europe Others Market by Country
  • 7.2.4Europe Hyperpigmentation Treatment Market by Country
    • 7.2.4.1Germany Hyperpigmentation Treatment Market
      • 7.2.4.1.1Germany Hyperpigmentation Treatment Market by Treatment Type
      • 7.2.4.1.2Germany Hyperpigmentation Treatment Market by End User
      • 7.2.4.1.3Germany Hyperpigmentation Treatment Market by Disorder Type
    • 7.2.4.2UK Hyperpigmentation Treatment Market
      • 7.2.4.2.1UK Hyperpigmentation Treatment Market by Treatment Type
      • 7.2.4.2.2UK Hyperpigmentation Treatment Market by End User
      • 7.2.4.2.3UK Hyperpigmentation Treatment Market by Disorder Type
    • 7.2.4.3France Hyperpigmentation Treatment Market
      • 7.2.4.3.1France Hyperpigmentation Treatment Market by Treatment Type
      • 7.2.4.3.2France Hyperpigmentation Treatment Market by End User
      • 7.2.4.3.3France Hyperpigmentation Treatment Market by Disorder Type
    • 7.2.4.4Russia Hyperpigmentation Treatment Market
      • 7.2.4.4.1Russia Hyperpigmentation Treatment Market by Treatment Type
      • 7.2.4.4.2Russia Hyperpigmentation Treatment Market by End User
      • 7.2.4.4.3Russia Hyperpigmentation Treatment Market by Disorder Type
    • 7.2.4.5Spain Hyperpigmentation Treatment Market
      • 7.2.4.5.1Spain Hyperpigmentation Treatment Market by Treatment Type
      • 7.2.4.5.2Spain Hyperpigmentation Treatment Market by End User
      • 7.2.4.5.3Spain Hyperpigmentation Treatment Market by Disorder Type
    • 7.2.4.6Italy Hyperpigmentation Treatment Market
      • 7.2.4.6.1Italy Hyperpigmentation Treatment Market by Treatment Type
      • 7.2.4.6.2Italy Hyperpigmentation Treatment Market by End User
      • 7.2.4.6.3Italy Hyperpigmentation Treatment Market by Disorder Type
    • 7.2.4.7Rest of Europe Hyperpigmentation Treatment Market
      • 7.2.4.7.1Rest of Europe Hyperpigmentation Treatment Market by Treatment Type
      • 7.2.4.7.2Rest of Europe Hyperpigmentation Treatment Market by End User
      • 7.2.4.7.3Rest of Europe Hyperpigmentation Treatment Market by Disorder Type
• 7.3Asia Pacific Hyperpigmentation Treatment Market
  • 7.3.1Asia Pacific Hyperpigmentation Treatment Market by Treatment Type
    • 7.3.1.1Asia Pacific Topical Agent Market by Country
    • 7.3.1.2Asia Pacific Photo Therapy Market by Country
    • 7.3.1.3Asia Pacific Microdermabrasion Market by Country
  • 7.3.2Asia Pacific Hyperpigmentation Treatment Market by End User
    • 7.3.2.1Asia Pacific Dermatological Clinics Market by Country
    • 7.3.2.2Asia Pacific Hospitals Market by Country
    • 7.3.2.3Asia Pacific Others Market by Country
  • 7.3.3Asia Pacific Hyperpigmentation Treatment Market by Disorder Type
    • 7.3.3.1Asia Pacific Melasma Market by Country
    • 7.3.3.2Asia Pacific Age Spot Market by Country
    • 7.3.3.3Asia Pacific Others Market by Country
  • 7.3.4Asia Pacific Hyperpigmentation Treatment Market by Country
    • 7.3.4.1China Hyperpigmentation Treatment Market
      • 7.3.4.1.1China Hyperpigmentation Treatment Market by Treatment Type
      • 7.3.4.1.2China Hyperpigmentation Treatment Market by End User
      • 7.3.4.1.3China Hyperpigmentation Treatment Market by Disorder Type
    • 7.3.4.2Japan Hyperpigmentation Treatment Market
      • 7.3.4.2.1Japan Hyperpigmentation Treatment Market by Treatment Type
      • 7.3.4.2.2Japan Hyperpigmentation Treatment Market by End User
      • 7.3.4.2.3Japan Hyperpigmentation Treatment Market by Disorder Type
    • 7.3.4.3India Hyperpigmentation Treatment Market
      • 7.3.4.3.1India Hyperpigmentation Treatment Market by Treatment Type
      • 7.3.4.3.2India Hyperpigmentation Treatment Market by End User
      • 7.3.4.3.3India Hyperpigmentation Treatment Market by Disorder Type
    • 7.3.4.4South Korea Hyperpigmentation Treatment Market
      • 7.3.4.4.1South Korea Hyperpigmentation Treatment Market by Treatment Type
      • 7.3.4.4.2South Korea Hyperpigmentation Treatment Market by End User
      • 7.3.4.4.3South Korea Hyperpigmentation Treatment Market by Disorder Type
    • 7.3.4.5Singapore Hyperpigmentation Treatment Market
      • 7.3.4.5.1Singapore Hyperpigmentation Treatment Market by Treatment Type
      • 7.3.4.5.2Singapore Hyperpigmentation Treatment Market by End User
      • 7.3.4.5.3Singapore Hyperpigmentation Treatment Market by Disorder Type
    • 7.3.4.6Malaysia Hyperpigmentation Treatment Market
      • 7.3.4.6.1Malaysia Hyperpigmentation Treatment Market by Treatment Type
      • 7.3.4.6.2Malaysia Hyperpigmentation Treatment Market by End User
      • 7.3.4.6.3Malaysia Hyperpigmentation Treatment Market by Disorder Type
    • 7.3.4.7Rest of Asia Pacific Hyperpigmentation Treatment Market
      • 7.3.4.7.1Rest of Asia Pacific Hyperpigmentation Treatment Market by Treatment Type
      • 7.3.4.7.2Rest of Asia Pacific Hyperpigmentation Treatment Market by End User
      • 7.3.4.7.3Rest of Asia Pacific Hyperpigmentation Treatment Market by Disorder Type
• 7.4LAMEA Hyperpigmentation Treatment Market
  • 7.4.1LAMEA Hyperpigmentation Treatment Market by Treatment Type
    • 7.4.1.1LAMEA Topical Agent Market by Country
    • 7.4.1.2LAMEA Photo Therapy Market by Country
    • 7.4.1.3LAMEA Microdermabrasion Market by Country
  • 7.4.2LAMEA Hyperpigmentation Treatment Market by End User
    • 7.4.2.1LAMEA Dermatological Clinics Market by Country
    • 7.4.2.2LAMEA Hospitals Market by Country
    • 7.4.2.3LAMEA Others Market by Country
  • 7.4.3LAMEA Hyperpigmentation Treatment Market by Disorder Type
    • 7.4.3.1LAMEA Melasma Market by Country
    • 7.4.3.2LAMEA Age Spot Market by Country
    • 7.4.3.3LAMEA Others Market by Country
  • 7.4.4LAMEA Hyperpigmentation Treatment Market by Country
    • 7.4.4.1Brazil Hyperpigmentation Treatment Market
      • 7.4.4.1.1Brazil Hyperpigmentation Treatment Market by Treatment Type
      • 7.4.4.1.2Brazil Hyperpigmentation Treatment Market by End User
      • 7.4.4.1.3Brazil Hyperpigmentation Treatment Market by Disorder Type
    • 7.4.4.2Argentina Hyperpigmentation Treatment Market
      • 7.4.4.2.1Argentina Hyperpigmentation Treatment Market by Treatment Type
      • 7.4.4.2.2Argentina Hyperpigmentation Treatment Market by End User
      • 7.4.4.2.3Argentina Hyperpigmentation Treatment Market by Disorder Type
    • 7.4.4.3UAE Hyperpigmentation Treatment Market
      • 7.4.4.3.1UAE Hyperpigmentation Treatment Market by Treatment Type
      • 7.4.4.3.2UAE Hyperpigmentation Treatment Market by End User
      • 7.4.4.3.3UAE Hyperpigmentation Treatment Market by Disorder Type
    • 7.4.4.4Saudi Arabia Hyperpigmentation Treatment Market
      • 7.4.4.4.1Saudi Arabia Hyperpigmentation Treatment Market by Treatment Type
      • 7.4.4.4.2Saudi Arabia Hyperpigmentation Treatment Market by End User
      • 7.4.4.4.3Saudi Arabia Hyperpigmentation Treatment Market by Disorder Type
    • 7.4.4.5South Africa Hyperpigmentation Treatment Market
      • 7.4.4.5.1South Africa Hyperpigmentation Treatment Market by Treatment Type
      • 7.4.4.5.2South Africa Hyperpigmentation Treatment Market by End User
      • 7.4.4.5.3South Africa Hyperpigmentation Treatment Market by Disorder Type
    • 7.4.4.6Nigeria Hyperpigmentation Treatment Market
      • 7.4.4.6.1Nigeria Hyperpigmentation Treatment Market by Treatment Type
      • 7.4.4.6.2Nigeria Hyperpigmentation Treatment Market by End User
      • 7.4.4.6.3Nigeria Hyperpigmentation Treatment Market by Disorder Type
    • 7.4.4.7Rest of LAMEA Hyperpigmentation Treatment Market
      • 7.4.4.7.1Rest of LAMEA Hyperpigmentation Treatment Market by Treatment Type
      • 7.4.4.7.2Rest of LAMEA Hyperpigmentation Treatment Market by End User
      • 7.4.4.7.3Rest of LAMEA Hyperpigmentation Treatment Market by Disorder Type

Chapter 8.Company Profiles

• 8.1Vivier Pharma Inc.
  • 8.1.1Company Overview
  • 8.1.2SWOT Analysis
• 8.2Pierre Fabre S.A
  • 8.2.1Company Overview
  • 8.2.2Recent strategies and developments:
    • 8.2.2.1Partnerships, Collaborations, and Agreements:
  • 8.2.3SWOT Analysis
• 8.3Aerolase
  • 8.3.1Company Overview
  • 8.3.2SWOT Analysis
• 8.4L'Oreal S.A.
  • 8.4.1Company Overview
  • 8.4.2Financial Analysis
  • 8.4.3Segmental and Regional Analysis
  • 8.4.4Recent strategies and developments:
    • 8.4.4.1Partnerships, Collaborations, and Agreements:
  • 8.4.5SWOT Analysis
• 8.5The Procter & Gamble Company
  • 8.5.1Company Overview
  • 8.5.2Financial Analysis
  • 8.5.3Segmental and Regional Analysis
  • 8.5.4Research & Development Expense
  • 8.5.5SWOT Analysis
• 8.6Galderma S.A.
  • 8.6.1Company Overview
  • 8.6.2SWOT Analysis
• 8.7CP Skin Health Group, Inc. (The Colgate Palmolive Company)
  • 8.7.1Company Overview
  • 8.7.2Financial Analysis
  • 8.7.3Segmental and Regional Analysis
  • 8.7.4Research & Development Expenses
  • 8.7.5SWOT Analysis
• 8.8Trophy Skin Products LLC
  • 8.8.1Company Overview
  • 8.8.2SWOT Analysis
• 8.9The Alchemee LLC (Taro Pharmaceutical Industries Ltd.)
  • 8.9.1Company Overview
  • 8.9.2Financial Analysis
  • 8.9.3Regional Analysis
  • 8.9.4Research & Development Expenses
  • 8.9.5SWOT Analysis
• 8.10.Episciences, Inc.
  • 8.10.1Company Overview
  • 8.10.2SWOT Analysis

Chapter 9.Winning Imperatives of Hyperpigmentation Treatment Market

관련자료